Whitehawk Therapeutics
WHWK
22 hedge funds and large institutions have $5.54M invested in Whitehawk Therapeutics in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.
0.1% less ownership
Funds ownership: 1.56% → 1.46% (-0.1%)
8% less funds holding
Funds holding: 24 → 22 (-2)
14% less capital invested
Capital invested by funds: $6.46M → $5.54M (-$912K)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$137K |
| 2 |
VF
Virtu Financial
New York
|
+$20.6K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$14.8K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$3.73K |
| 5 |
BlackRock
New York
|
+$800 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$344K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$127K |
| 3 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$24K |
| 4 |
Jane Street
New York
|
-$24K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Citadel Advisors
Miami,
Florida
| – | -$14K | -1,422 | Closed |
|
WHWK Hedge Fund Activity: Q4 2019 in Review
22 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q4 2019, worth a combined $5.54M — down 14% from $6.46M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of WHWK and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $137K. The largest seller was Goldman Sachs, cutting an estimated $344K.
- 22 institutional investors held Whitehawk Therapeutics (WHWK) as of Q4 2019, down from 24 in Q3 2019.
- Funds reported $5.54M of Whitehawk Therapeutics stock for Q4 2019, down 14% quarter-over-quarter.
- 2 funds opened new Whitehawk Therapeutics positions in Q4 2019 and 4 closed out, a net change of -2 holders.
- The largest Whitehawk Therapeutics buyer in Q4 2019 was Renaissance Technologies, an estimated $137K added.
- The largest Whitehawk Therapeutics seller in Q4 2019 was Goldman Sachs, an estimated $344K sold.
Based on aggregated 13F filings for Q4 2019.